Liposomal formulation of polyacrylate-peptide conjugate as a new vaccine candidate against cervical cancer

Peptide-based vaccines have been proposed as a therapeutic strategy for many infectious diseases, including human papilloma virus (HPV)-related cervical cancer. Peptide-based vaccines are a better treatment option than traditional chemotherapeutic agents and surgery, as they rely on the use of the b...

Full description

Saved in:

Bibliographic Details
Published in:	Precision nanomedicine 2018-12, Vol.1 (3), p.183-193
Main Authors:	Toth, Istvan, Khongkow, Mattaka, Liu, Tzu-yu, Bartlett, Stacey, Hussein, Waleed M, Nevagi, Reshma, Jia, Zhogfan, Monteiro, Michael J, Wells, James, Ruktanonchai, Uracha Rungsardthong, Skwarczynski, Mariusz
Format:	Article
Language:	eng
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Peptide-based vaccines have been proposed as a therapeutic strategy for many infectious diseases, including human papilloma virus (HPV)-related cervical cancer. Peptide-based vaccines are a better treatment option than traditional chemotherapeutic agents and surgery, as they rely on the use of the body’s immune system to fight cancer cells, resulting in minimal risk of side effects. However, to increase the efficacy of peptide-based vaccines, the application of potent adjuvant and a suitable delivery system is essential. In this study, we developed a self-adjuvanting delivery system based on a combination of polymer and liposomes, for a therapeutic vaccine against cervical cancer. Peptide epitope (8Qm) derived from HPV-16 E7 protein was conjugated to dendritic poly(tert-butyl acrylate) as a primary delivery system and incorporated into cationic liposomes, which served as a secondary delivery system. Our vaccine candidate was able to kill established HPV-16 E7-positive tumor (TC-1) cells in mice following a single immunization. The immunized mice had 80% survival rate after two months. In contrast, both polymer-8Qm conjugate and liposomes bearing 8Qm failed to eradicate TC-1 tumors. The survival rate of mice was only 20% when immunized with 8Qm formulated with standard incomplete Freund’s adjuvant.
ISSN:	2639-9431 2639-9431